Pfizer (PFE) Total Current Liabilities (2009 - 2026)

Pfizer (PFE) has 18 years of Total Current Liabilities data on file, last reported at $34.3 billion in Q1 2026.

• Quarterly Total Current Liabilities fell 5.77% year-over-year to $34.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.3 billion (down 5.77% YoY) and the FY2025 annual result came in at $37.0 billion, down 13.98% from the prior year.
• Total Current Liabilities retreated to $34.3 billion in Q1 2026 per PFE's latest filing, from $37.0 billion in the prior quarter.
• Across five years, Total Current Liabilities topped out at $47.8 billion in Q4 2023 and bottomed at $5.2 billion in Q4 2022.
• The 5-year median for Total Current Liabilities is $37.7 billion (2025), against an average of $37.5 billion.
• Peak annual rise in Total Current Liabilities reached 494.77% in 2023, while the deepest fall reached 26.92% in 2023.
• Tracing PFE's Total Current Liabilities over 5 years: stood at $42.1 billion in 2022, then advanced by 13.42% to $47.8 billion in 2023, then retreated by 10.04% to $43.0 billion in 2024, then slipped by 13.98% to $37.0 billion in 2025, then dropped by 7.13% to $34.3 billion in 2026.
• Per Business Quant, the three latest PFE Total Current Liabilities figures stand at $34.3 billion (Q1 2026), $37.0 billion (Q4 2025), and $36.6 billion (Q3 2025).

Peer Comparison